ArticleKidney international2014
The 2014International Workshop on Alport Syndrome.
Article in Kidney international, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed, 1 synthesis or guideline pooled it, 50 citations in OpenAlex.
- KDIGO Clinical Practice Guideline on the Evaluation and Care of Living Kidney Donors.Transplantation · 2017Guideline
- Working together to diagnose rare kidney disease earlier.Nature reviews. Nephrology · 2026Article
- Update on Alport Syndrome: The Report of the 2024 International Workshop on Alport Syndrome.Kidney international reports · 2026Article
- A Novel Loss-of-Function Variant in COL4A3 in a Consanguineous Moroccan Family Displaying the Alport Syndrome with Variable Clinical Expression.Molecular syndromology · 2025Article
- Genetic study of Alport syndrome in Tunisia.Pediatric nephrology (Berlin, Germany) · 2025Article
- Population-based studies reveal an additive role of type IV collagen variants in hematuria and albuminuria.Pediatric nephrology (Berlin, Germany) · 2022Review
- Temporal retinal thinning might be an early diagnostic indicator in male pediatric X-linked Alport syndrome.International journal of ophthalmology · 2022Article
- Genotype-phenotype correlations and nephroprotective effects of RAAS inhibition in patients with autosomal recessive Alport syndrome.Pediatric nephrology (Berlin, Germany) · 2021Article
- Functional assessment of a novelAnnals of translational medicine · 2021Article
- Clinical trial recommendations for potential Alport syndrome therapies.Kidney international · 2020Article
- The importance of clinician, patient and researcher collaborations in Alport syndrome.Pediatric nephrology (Berlin, Germany) · 2020Article
- Kidney disease trials for the 21st century: innovations in design and conduct.Nature reviews. Nephrology · 2020Review
- Relationships between dipstick proteinuria and risk of hearing impairment among Japanese workers: a prospective cohort study.BMJ open · 2019Article
- Femtosecond laser-assisted cataract surgery in Alport's syndrome - A case report.Indian journal of ophthalmology · 2019Article
- Expert consensus guidelines for the genetic diagnosis of Alport syndrome.Pediatric nephrology (Berlin, Germany) · 2019Review
- Alport Patients without Classic Ocular Symptoms Have Smaller Lens Diameter.Medical science monitor : international medical journal of experimental and clinical research · 2019Article
- X-linked Alport syndrome: pathogenic variant features and further auditory genotype-phenotype correlations in males.Orphanet journal of rare diseases · 2018Article
- Anterior lenticonus associated with Alport syndrome.Indian journal of ophthalmology · 2018Article
- Laminin-521 Protein Therapy for Glomerular Basement Membrane and Podocyte Abnormalities in a Model of Pierson Syndrome.Journal of the American Society of Nephrology : JASN · 2018Article
- Pathogenicity of a Human LamininJournal of the American Society of Nephrology : JASN · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
18 authors at 12 institutions in 6 countries.
Funding
Abstract
Alport syndrome, historically referred to as hereditary glomerulonephritis with sensorineural deafness and anterior lenticonus, is a genetic disease of collagen α3α4α5(IV) resulting in renal failure. The collagen α3α4α5(IV) heterotrimer forms a network that is a major component of the kidney glomerular basement membrane (GBM) and basement membranes in the cochlea and eye. Alport syndrome, estimated to affect 1 in 5000-10,000 individuals, is caused by mutations in any one of the three genes that encode the α chain components of the collagen α3α4α5(IV) heterotrimer: COL4A3, COL4A4, and COL4A5. Although angiotensin-converting enzyme inhibition is effective in Alport syndrome patients for slowing progression to end-stage renal disease, it is neither a cure nor an adequate long-term protector. The 2014 International Workshop on Alport Syndrome, held in Oxford, UK, from January 3-5, was organized by individuals and families living with Alport syndrome, in concert with international experts in the clinical, genetic, and basic science aspects of the disease. Stakeholders from diverse communities-patient families, physicians, geneticists, researchers, Pharma, and funding organizations-were brought together so that they could meet and learn from each other and establish strategies and collaborations for the future, with the overall aim of discovering much needed new treatments to prolong kidney function.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.